Abstract: The cell-mesenchymal epithelial transition factor (c-Met) plays a critical role in the initiation and progression of cancer and is overexpressed in a variety of tumors. Therefore, c-MET has emerged as an important target for tumor diagnosis and therapy. The combination of c-MET-targeted probes with PET enables real-time detection of c-MET target expression in vivo, allowing for non-invasive and real-time diagnosis of tumors. This approach facilitates improved selection of treatment strategies, enables personalized therapy for cancer patients, and promotes the development of more anti-cancer drugs. The authors have summarized research progress on the application and clinical translation of c-MET-targeted PET imaging agent in tumor diagnosis and therapy, aiming to elucidate the pathways and challenges in their clinical translation toward ultimately achieving personalized precision medicine in the field of oncology.